Exhibit 10.47

                          CONSULTING SERVICES AGREEMENT

This AGREEMENT ("AGREEMENT") is entered into as of  August 1-, 2006, by DNAPrint
genomics,  Inc.,  900  Cocoanut  Ave.,  Sarasota, FL 34236, USA ("DNAP") and DR.
ARTHUR J. SYTKOWSKI residing at 203 Park Avenue, Arlington, Massachusetts 02476,
USA  ("DR.  SYTKOWSKI").

                                   WITNESSETH:

     WHEREAS,  DNAP  is  engaged  in a project (the "PROJECT") relating to human
erythropoietin  (the  "FIELD");  and

     WHEREAS, DR. SYTKOWSKI has knowledge and expertise regarding the FIELD; and

     WHEREAS,  DNAP  desires  to  make  use  of  the  specialized  knowledge and
expertise  of  DR.  SYTKOWSKI  as  a  consultant  in  the  FIELD;  and

     WHEREAS,  DR.  SYTKOWSKI  has  advised DNAP of his willingness, ability and
desire  to provide consulting and advisory services to it in connection with the
FIELD;

NOW,  THEREFORE,  in  consideration  of  the  mutual  covenants  and  conditions
contained  herein,  DR.  SYTKOWSKI  and  DNAP  agree  as  follows:

1.  ENGAGEMENT  -  DNAP  hereby  engages  DR. SYTKOWSKI and DR. SYTKOWSKI hereby
    ----------
agrees  to hold himself available and to render, at DNAP's  request, independent
   --
advisory  and  consulting  services, in compliance with the terms and conditions
set  forth  herein  and  all  applicable  laws,  statutes  and  regulations.

2.  SERVICES  AND  DUTIES  -  DR.  SYTKOWSKI agrees that during the term of this
    ---------------------
AGREEMENT and any subsequent extension(s) thereof,  he will provide his services
   --
as  a  consultant  to  DNAP in the FIELD. DR. SYTKOWSKI's responsibilities shall
include,  but  shall  not  be  limited  to,  the  following  services:

a. Consulting on all matters involving the FIELD, including, without limitation,
implementation  of  analytics, purification, medical uses, regulatory issues and
patent  affairs;

b.  Advising  and training personnel designated by DNAP in the FIELD technology;

c.  Advising  on  the  status  of  FIELD-  related  patents  and  prosecutions;

d.  Advising  on  clinical  trials,  medical uses and side effects of the FIELD;

e.  Providing  information  on  new  developments  in  the  FIELD;

f. Providing expertise and introduction to  DR. SYTKOWSKI's personal contacts in
the  FIELD,  including  without  limitation,  scientific,  medical,  biotech,
regulatory  and  patent  issues;  and,

g.  Working  on  the  Tasks  described  on  the  attached  Exhibit  "A".

DR.  SYTKOWSKI further agrees to render his services conscientiously, consistent
with the highest standards of his profession, and to devote, subject to existing
professional  duties,  the  requisite  time,  effort  and  abilities required to
satisfactorily perform his obligations during the term of this AGREEMENT and any
subsequent  extension(s) thereto, and to do so in such reasonable manner as DNAP
and  DR.  SYTKOWSKI  shall  mutually  agree.

3.  PAYMENT  - As full consideration for the services performed by DR. SYTKOWSKI
    -------
hereunder,  DNAP  agrees  to  compensate  DR.  SYTKOWSKI  as  follows:

     a.  ONE  HUNDRED AND TWENTY THOUSAND ($ 120,000.00) U.S. DOLLARS to be paid
in  twelve equal monthly installments of TEN THOUSAND ($10,000.00) U.S. DOLLARS.
Each  payment  will  be  made  within  THIRTY (30) DAYS of the first day of each
month,  with  the  first  month  commencing  on  the  date  of execution hereof.

     b.  Upon  presentation  of  receipts, DNAP will reimburse DR. SYTKOWSKI for
reasonable out-of-pocket expenses incurred in connection with services performed
under  this  AGREEMENT,  including  but  not limited to airfare, lodging, meals,
taxis,  trains,  extraordinary fee-based computer searches and the like. Flights
of  greater  than  two (2) hours will be business class or the next higher class
above  economy, if DR. SYTKOWSKI so chooses. DR. SYTKOWSKI will invoice DNAP for
such  travel  and  other expenses promptly after incurring such charges and DNAP
agrees to pay such invoices, subject to the conditions of this paragraph, within
THIRTY  (30)  DAYS  of  their  receipt.

     c.  DNAP  agrees  to  reimburse  DR. SYTKOWSKI for airfare, lodging, meals,
taxis,  trains,  and  all  other  reasonable  out-of-pocket expenses incurred in
conjunction  with  attending  two  scientific/medical,  biotechnology  or
pharmaceutical  related  meetings  per year, said meetings to relate directly to
the  FIELD and/or to DR. SYTKOWSKI's consulting and advisory services under this
AGREEMENT.  DR.  SYTKOWSKI  shall  obtain DNAP's consent prior to incurring such
expenses.  DR.  SYTKOWSKI  agrees  to invoice DNAP promptly after incurring such
charges  and  DNAP  agrees to pay such invoices within THIRTY (30) DAYS of their
receipt.

     d.  In  recognition  of DR. SYTKOWSKI's knowledge and skill, DNAP agrees to
make  five  separate  incentive  payments to DR. SYTKOWSKI at the rate of TWENTY
FIVE  THOUSAND  ($25,000.00)  U.S. DOLLARS per year to be paid on or before each
anniversary  of  the  date  of  execution  hereof.

4.  MILESTONE  CONTINGENT  PAYMENTS- DNAP agrees to make the following milestone
  ---------------------------------
payments to DR. SYTKOWSKI following the completion of the described event to the
satisfaction  of  DNAP,  and  to  the  extent DR. SYTKOWSKI has not received any
monies  from Beth Israel Deaconess Medical Center ("BIDMC") under any agreements
between  DR.  SYTKOWSKI  and  BIDMC  relating  to  the  described  event:

a.     Initiation  of  the  first  Phase  I  trial  of  an  erythropoietin  or
erythropoietin-related  product, TWENTY FIVE THOUSAND ($25,000.00) U.S. DOLLARS.
b.     Initiation  of  the  first  Phase  II  trial  of  an  erythropoietin  or
erythropoietin-related  product, TWENTY FIVE THOUSAND ($25,000.00) U.S. DOLLARS.
c.     First  regulatory approval of an erythropoietin or erythropoietin-related
product,  TWENTY  FIVE  THOUSAND  ($25,000.00)  U.S.  DOLLARS.
d.     First  commercial  sale  of  an  erythropoietin or erythropoietin-related
product,  FIFTY  THOUSAND  ($50,000.00)  U.S.  DOLLARS.

DNAP's  obligation  to  make these payments to DR. SYTKOWSKI will extend for ten
(10)  years  beyond  the  term of this AGREEMENT, or any termination, renewal or
extension  thereof.  Any  payments DR. SYTKOWSKI receives from BIDMC relating to
the  described  events  shall  reduce,  dollar  for  dollar,  DNAP's obligations
hereunder.

5.  INDEMNIFICATION  -  DNAP  shall  indemnify,  defend  and  hold  harmless DR.
    ---------------
SYTKOWSKI  and  his  employees and agents and their respective heirs, successors
   -----
and assigns (the "INDEMNITEES"), against any liability, damage, loss, or expense
(including  attorneys'  fees and expenses of litigation) actually incurred by or
imposed  upon  the INDEMNITEES or any one of them in connection with any claims,
suits,  actions,  demands, or judgments of any party other than DNAP arising out
of  or  relating  to  the  PROJECT, including, but not limited to, any theory of
product  liability  (including  but not limited to, strict liability) concerning
any  products,  process  or  service  made,  used or sold pursuant to any rights
granted  under  this  AGREEMENT.  DNAP's  indemnification shall not apply to any
claim,  suit,  action,  demand,  loss  or expense (including attorneys' fees and
expenses of litigation) to the extent that it is actually incurred or imposed or
is  due  to the breach of this AGREEMENT, violation of or failure to comply with
any  law,  or  governmental  regulation,  negligence,  reckless  MISCONDUCT  or
intentional  MISCONDUCT  (hereinafter collectively the " MISCONDUCT ") of any of
the  INDEMNITEES.

6.  CONFIDENTIALITY  -  In  view of the proprietary rights and interests of DNAP
    ---------------
concerning the PROJECT and their facilities and technology, DR. SYTKOWSKI agrees
that  during the term of this AGREEMENT and any subsequent extension(s) thereto,
and  for  a  period  of  three (3) years thereafter, DR. SYTKOWSKI shall hold in
strictest  confidence  and not use for his own benefit or for the benefit of any
third  party  any  information concerning the PROJECT and DNAP (including DNAP's
security  and computer systems) or the FIELD which is disclosed to DR. SYTKOWSKI
by DNAP or that results from his services under this AGREEMENT. Such information
includes,  but  is  not  limited  to,  confidential  or proprietary information,
discoveries,  results,  methodology,  codes,  passwords,  materials, technology,
know-how,  financial  and  other  data,  both  technical  and non-technical. DR.
SYTKOWSKI  shall  not  disclose  nor  cause  nor  permit  to  be  disclosed such
information  to  any third party or use such information for any purpose, except
as  provided  herein,  without the prior written approval of DNAP. The foregoing
restrictions  and obligations of DR. SYTKOWSKI shall not apply to any portion of
such  information  which:

a.  Is or later becomes generally available to the public by use, publication or
the  like,  through  no  fault  of  DR.  SYTKOWSKI;

b.  Is  obtained from a third party who had the legal right to disclose the same
to  DR.  SYTKOWSKI;  or

c.  Is  already possessed by DR. SYTKOWSKI, as evidenced by his written records,
predating  receipt  thereof  from  DNAP.

Specific  information  disclosed to DR. SYTKOWSKI by DNAP shall not be deemed to
be  available  to  the  public  or  in  prior possession of DR. SYTKOWSKI merely
because  such  specific  information  is  embraced  by  more general information
available  to  the  public  or  in  the  prior  possession  of  DR.  SYTKOWSKI.

7.  RIGHT  TO  DISCLOSE  -  DR.  SYTKOWSKI  agrees  that during the term of this
    -------------------
AGREEMENT,  he  will  not  disclose  to DNAP any information which he is under a
   ----
contractual  or  other  legal  obligation  to  a  third  party  not to disclose.
   -

8.  TERM,  TERMINATION AND EXTENSION OF THIS AGREEMENT - This AGREEMENT shall be
    --------------------------------------------------
effective  for  a  twelve  (12) month Period beginning August 1, 2006 and ending
July  31,  2007.

Either  party  may terminate this AGREEMENT upon ninety (90) days written notice
to the other party. If DNAP terminates this AGREEMENT for DR. SYTKOWSKI's breach
of this AGREEMENT, or DR. SYTKOWSKI's violation of or failure to comply with any
law,  or  governmental regulation, negligence or MISCONDUCT, DR. SYTKOWSKI shall
not  be  entitled  to  receive  the  Milestone payments referenced in Section 4,
above.  Any  rights  or obligations set forth herein, which are accrued prior to
the  termination of this AGREEMENT, shall survive termination of this AGREEMENT.
Negotiations  may  be  initiated  at  the  request  of  either  party  prior  to
termination  of  this  AGREEMENT to extend this AGREEMENT. If the parties do not
agree  on  an  extension  in writing prior to July 15, 2006, the AGREEMENT shall
terminate  on  July  31,  2006.

9.  INDEPENDENT  CONTRACTOR  -  For the purpose of this AGREEMENT, DR. SYTKOWSKI
    -----------------------
shall  be an independent contractor of DNAP without the authority to bind or act
as  agent  for  DNAP  or  its  employees  for  any  purpose, and nothing in this
AGREEMENT shall be construed to create any joint venture or partnership among or
between  the  parties.

10.  PUBLICITY  -  Neither  party  will  use  the  name  of  the  other party in
     ---------
publication  or  advertising  involving this AGREEMENT without the other party's
    ------
prior  written  approval.

11.  WARRANTIES  -   The  parties warrant and represent that they have the right
     ----------
to  enter  into  and  perform this AGREEMENT. DR. SYTKOWSKI further warrants and
represents  that he knows of no conflict between the terms of this AGREEMENT and
any  other  contractual or other obligations, expressed or implied, which he may
have  with  anyone,  including but not limited to his contractual obligations to
Beth  Israel  Deaconess  Medical  Center.

12.  GOVERNING  LAW  -  This  AGREEMENT  shall  be  governed  by the laws of the
     --------------
Commonwealth  of Massachusetts, USA, and DR. SYTKOWSKI and DNAP hereby submit to
    ----
the  exclusive jurisdiction of the Massachusetts Courts, both State and Federal.

13.  AMENDMENTS  -  No  modification to this AGREEMENT shall be effective unless
     ----------
made  in  writing  and signed by a duly authorized representative of each party.

14.  NOTICES  - All notices required or permitted to be given hereunder shall be
     -------
in  writing  and given to each of the other parties hereto by delivery to its or
his  respective  address as first set forth above by (i) personal delivery, (ii)
courier  service  or registered or certified air mail (postage prepaid) or (iii)
by fax (with a copy by registered or certified air mail). All such notices shall
be  effective  when  received  by  the  addressee.

15. TAXES -Each party shall be responsible for his or its own tax obligations as
    -----
imposed  by  any  governmental  authority  having  jurisdiction.

16. ASSIGNMENT - This AGREEMENT may not be assigned without the parties' express
    ----------
written  consent.  Any  purported assignment of this AGREEMENT is void and of no
effect.



IN  WITNESS  WHEREOF,  the  parties have executed this AGREEMENT as of dates set
forth  below:

DR.  ARTHUR  J.  SYTKOWSKI               DNAPrint  genomics,  Inc.

Date:                                    Name  (print):

Place:                                   Date:

Signature:                               Place:

                                         Signature:

<PAGE>
                                    EXHIBIT A

The studies outlined below will require more than one year to complete. However,
each  study  can be emphasized depending upon priorities agreed upon by DNAP and
Dr.  Sytkowski.


  SUPERVISE STUDIES SUPPORTING EPO DIMER DEVELOPMENT AND PRODUCT DIFFERENTIATION
        COMPARING EPO DIMER, CONVENTIONAL EPO AND DARBEPOETIN (ARANESPTM)

-     Quantify  parameters  of  binding  to  the  Epo  receptor  (EpoR).

      o     On  and  off  rate  constants;  equilibrium  dissociation  constant
      o     Receptor  internalization  and  recycling  to  cell  surface
      o     Hill  coefficient

-     Quantify  intracellular  signal  strength  and  duration  for  growth  and
differentiation

-     Gene expression studies: compare qualitative and quantitative differences.

-     Compare  results  for  hematopoietic  cell  EpoR with EpoR on other cells,
e.g.,  endothelial  cells,  neuronal  cells.

-     Complete  development  of  anti-Epo  antibody  assays  required  by  FDA

-     Interact with CRO personnel including transfer of and training in analytic
techniques.

-     Carry  out  in  vitro  bioassays  of samples provided by CRO. The assay is
calibrated  against  the  World  Health  Organization  International  Reference
Preparation  of  human  erythropoietin.

-     Carry  out  in  vivo  bioassays  of  samples  provided  by  CRO

<PAGE>

    SUPERVISE RESEARCH AND DEVELOPMENT OF NEW PHARMACEUTICAL AGENTS BASED UPON
                               LICENSED TECHNOLOGY

-     Explore  polyethylene  glycol  derivatization  (PEGylation)  of  Epo dimer

      o     Test  alternative  chemistries
      o     Vary  stoichiometry
      o     Preliminary  PK  and  PD

-     Begin  development  of  R103A  mutant  for  tissue  protection (neuro- and
cardioprotection)

      o     Prepare  stably  expressing  CHO  cell  line
      o     Develop  in  vitro  assays  to  test  tissue  protective  effects
      o     Validate  R103A  as  a  tissue  protective  agent  in  vivo